The pharmaceutical industry has developed the preparation of ketamine called esketamine which, instead of having to inject intravenously, can be inhaled under medical surveillance, of course.
And there are at least three trials ongoing in different countries, in different centres. We are one of the centers and if everything goes well we're talking probably about commercialization in late 2019.
It could have a major impact because, for example, it could be given to people who have had treatment resistance. And then we would have the capacity to get them well very fast. And then more research will have to be carried out to see if it could be used earlier in the sequence of treatment. And like I mentioned before almost everybody experiences a decrease in suicidal ideation. And that's the major impact because there are 4,000 Canadians dying from suicide in Canada every year, 11 a day.
Check out the aricle, or the radio episode.
I'm willing to try anything to feel better - I don't care of it's horse tranquilizer.